Today: 19 May 2026
Carnival stock price jumps 8% as SEC filing flags possible CFO share sale next week
7 February 2026
1 min read

Carnival stock price jumps 8% as SEC filing flags possible CFO share sale next week

New York, Feb 7, 2026, 05:17 EST — The session wrapped up with markets now closed.

  • Carnival finished the day at $33.99, gaining 8.1% on Friday.
  • A Form 144 filing flagged a possible sale of 361,790 shares, targeting about Feb. 10.
  • Eyes are on Feb. 13, the dividend record date, with attention shifting next to the upcoming earnings window in March.

Carnival Corp & plc shares jumped 8.1% to finish Friday at $33.99. The stock caught a lift from a broader risk-on rally, after a regulatory filing pointed to a potential executive share sale slated for early next week.

Timing is key here. After the stock’s steep rally, it’s particularly vulnerable to new supply hitting the market when Wall Street opens Monday. Traders, meanwhile, are eyeing several near-term corporate events on the calendar.

Late Friday, a Form 144 filing showed Carnival executive officer David Bernstein intends to offload 361,790 shares—roughly $11.6 million worth—through Citigroup Global Markets. The filing flagged Feb. 10 as the expected sale date.

Form 144 serves as a notice for a planned sale under SEC Rule 144, laying out the requirements for selling restricted or “control” securities. According to the filing, the shares originated from restricted stock units that vested in April 2023. It also made clear there haven’t been any sales in the past three months. StreetInsider.com

According to the company’s leadership page, Bernstein holds the titles of chief financial officer and chief accounting officer at Carnival.

Cruise stocks rallied Friday, with Royal Caribbean adding 6.7% by the close. Norwegian Cruise Line notched a 7.5% gain, according to trade data.

Carnival brought back its dividend in December, announcing a Feb. 13, 2026 record date after pandemic-related suspension. CEO Josh Weinstein at the time flagged booking volumes during Black Friday to Cyber Monday as “even outpacing prior year’s robust levels.” Over at Gimme Credit, analyst Kim Noland cited the resilience of the company’s “affordable packages” despite ongoing uncertainty. Reuters

Carnival’s overhaul of its dual-listed structure remains in focus. The company told investors that more shareholder materials should land in February, with meetings and votes slated for April.

The set-up here isn’t straightforward. Announcing a sale doesn’t necessarily mean shares will actually hit the tape, and after a rapid climb, even ordinary selling can rattle sentiment—particularly if broader markets shift or there’s a hiccup in travel spending headlines.

Traders now turn their attention to follow-up filings related to the proposed sale, as well as potential news on that February window for shareholder materials. According to analyst calendars, the next earnings report should land around March 20.

Stock Market Today

  • Thermon Group Q4 Earnings Miss Estimates Despite Revenue Beat
    May 19, 2026, 9:46 AM EDT. Thermon Group (THR) reported Q4 earnings of $0.55 per share, slightly missing the Zacks Consensus Estimate of $0.56, marking a -1.20% earnings surprise. Revenue reached $148.33 million, surpassing estimates by 9.70% and up from $134.08 million a year ago. The company has outperformed the S&P 500 with a 72.4% stock increase year-to-date versus the index's 8.1%. Thermon's earnings outlook remains mixed, resulting in a Zacks Rank #3 (Hold), suggesting near-term performance in line with the market. Consensus estimates for the upcoming quarter stand at $0.41 EPS and $115.28 million revenue. Industry trends within the Instruments - Control sector could further influence stock performance.

Latest articles

Relay Therapeutics Stock Jumps Before The Bell — The Drug Data Investors Are Watching

Relay Therapeutics Stock Jumps Before The Bell — The Drug Data Investors Are Watching

19 May 2026
New York, May 19, 2026, 09:03 EDT Relay Therapeutics Inc. shares rose before the bell on Tuesday after the Cambridge, Massachusetts-based biotech said its lead drug, zovegalisib, showed early signs of shrinking lesions in patients with rare vascular anomalies. The stock traded at $13.47 in premarket dealing at 09:03 EDT, up 11.3% from Monday’s close of $12.10, according to Investing.com data. The move came ahead of the regular Nasdaq session and against a softer tape for U.S. futures, with S&P 500 and Nasdaq futures recently down 0.4% and 0.8%, respectively. The readout matters because zovegalisib is no longer being watched
Rubico Shares Surge Before Market Open on Volume Spike

Rubico Shares Surge Before Market Open on Volume Spike

19 May 2026
Rubico Inc shares jumped 127.75% to $3.94 in U.S. premarket trading Tuesday, with volume surging to 34.04 million shares versus an average of 95,000. The move followed a May 8 SEC filing for a proposed unit offering with warrants, which could price below market. No new earnings report was released. Rubico operates two Suezmax crude-oil tankers and recently completed a one-for-10 reverse stock split.

Popular

Figma shares test rebound as AI bet delivers

Figma shares test rebound as AI bet delivers

18 May 2026
Figma traded at $23.20 Monday afternoon, valuing the company at $12.1 billion. First-quarter revenue jumped 46% to $333.4 million, and the company raised its 2026 revenue forecast to up to $1.428 billion. Paid customers rose 54% to about 690,000. Figma posted a GAAP net loss of $142.4 million but reported $56.5 million in non-GAAP net income.
Xero share price slides 14% in a week — what to watch next for ASX:XRO
Previous Story

Xero share price slides 14% in a week — what to watch next for ASX:XRO

Exxon Mobil stock price just tagged a new high — what could move XOM when markets reopen
Next Story

Exxon Mobil stock price just tagged a new high — what could move XOM when markets reopen

Go toTop